Compare WEAV & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEAV | SGHT |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 593.7M | 489.7M |
| IPO Year | 2021 | 2021 |
| Metric | WEAV | SGHT |
|---|---|---|
| Price | $7.40 | $8.30 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 8 |
| Target Price | $7.40 | ★ $10.17 |
| AVG Volume (30 Days) | ★ 1.4M | 337.0K |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.50 | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $239,024,000.00 | $77,363,000.00 |
| Revenue This Year | $14.72 | $16.75 |
| Revenue Next Year | $13.37 | $11.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.99 | N/A |
| 52 Week Low | $4.24 | $3.38 |
| 52 Week High | $7.70 | $9.71 |
| Indicator | WEAV | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 63.16 | 47.74 |
| Support Level | $7.29 | $7.77 |
| Resistance Level | $7.42 | $8.82 |
| Average True Range (ATR) | 0.02 | 0.50 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 63.64 | 27.77 |
Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and generates revenue mainly from subscriptions.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.